Ireland· IE-PA-PA23355/039/002
Relifex 1g film-coated tablets
A nabumetone product containing nabumetone, registered in Ireland by Viatris Healthcare Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nabumetone is registered in 14 of 19 countries.
Countries holding a registration under ATC M01AX01 (nabumetone), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Nabumetone · ATC M01AX01
14 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nabumetone costs, country by country.
Normalised to the WHO defined daily dose (1 g), the median price runs from $0.37 in France to $0.73 in Italy — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nabumetone · price per daily dose (1 g)
USD · FX 28 Sept 2026
- IT Italy$0.73
- FR France$0.37
The record
At a glance
HPRA (Ireland)- Active substance
- Nabumetone
- Manufacturer
- Viatris Healthcare Limited
- Country
- Ireland (IE)
- ATC code
- M01AX01
- ATC class
- Nabumetone
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA23355/039/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
289 interactions on record for nabumetone.
Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nabumetone · interactions on record
289 records
- 57 severe
- 142 moderate
- 4 minor
- 86 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nabumetone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRelifexMeda Oy
- NetherlandsMebutan 1 g, tablettenViatris Healthcare B.V.
- NorwayRelifexViatris AS
- United StatesNabumetone 1000 mgLGM PHARMA SOLUTIONS, LLC
- United KingdomNabumetone 500mg tabletsTillomed Laboratories Ltd
- BelgiumGambaran 500 mgViatris Healthcare
- ItalyNABUSER*30 cpr rivestite 1 gPHARMADAY PHARM.Srl UNIPERSONA
- SwedenRelifex 500 mg Filmdragerad tablettEbb Medical AB
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Belgium · Gambaran, Nabumeton Tillomed
- Germany · Relifex
- Estonia · Relifex
- Spain · Relif
- France · Nabucom
- United Kingdom (Northern Ireland) · Nabumetone Accord-Uk, Nabumetone Kent Pharma Uk
- Greece · Akratol, Nabuton
- Hungary · Relifex
- Iceland · Relifex
- Italy · Nabuser
- Lithuania · Relifex
- Luxembourg · Gambaran
- Latvia · Relifex
- Netherlands · Mebutan, Mebutan Dispers
- Norway · Relifex
- Poland · Nabuton Vp
- Sweden · Relifex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b400704e-1a1f-44bf-93cd-64bb7b571d2f GET /v1/drugs/b400704e-1a1f-44bf-93cd-64bb7b571d2f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"M01AX",
"M01AX01"
],
"strength": null,
"pa_number": "PA23355/039/002",
"substances": [
"Nabumetone"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "16/10/2009",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nabumetone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.